EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimal control of multiple myeloma assuming drug resistance and off-target effects

James G Lefevre iD, Brodie A J Lawson iD, Pamela M Burrage iD, Diane M Donovan, Kevin Burrage

PLOS Computational Biology · 2025

DOI: 10.1371/journal.pcbi.1012225 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Computational Biology, 2025. Verfasst von James G Lefevre und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Mathematics and Physics, The University of Queensland, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Multiple Myeloma, Drug Resistance, Neoplasm, Antibodies, Monoclonal, Models, Biological. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Research Council Centre of Excellence for Plant Success in Nature and Agriculture.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma (MM) is a plasma cell cancer that occurs in the bone marrow. A leading treatment for MM is the monoclonal antibody Daratumumab, targeting the CD38 receptor, which is highly overexpressed in myeloma cells. In this work we model drug resistance via loss of CD38 expression, which is a proposed mechanism of resistance to Daratumumab treatment. We develop an ODE model that includes drug resistance via two mechanisms: a direct effect in which CD38 expression is lost without cell death in response to Daratumumab, and an indirect effect in which CD38 expression switches on and off in the cancer cells; myeloma cells that do not express CD38 have lower fitness but are shielded from the drug action. The model also incorporates competition with healthy cells, death of healthy cells due to off-target drug effects, and a Michaelis-Menten type immune response. Using optimal control theory, we study the effect of the drug resistance mechanisms and the off-target drug effect on the optimal treatment regime. We identify a general increase in the duration and costs of optimal treatment, as a result of these added mechanisms. Several distinct optimal treatment regimes are identified within the parameter space.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaDrug Resistance, NeoplasmAntibodies, MonoclonalModels, BiologicalAntineoplastic AgentsHumansADP-ribosyl Cyclase 1Computational Biology

Substanzen

Antibodies, MonoclonaldaratumumabADP-ribosyl Cyclase 1Antineoplastic Agents

Autor:innen und Institutionen

  • School of Mathematics and Physics, The University of Queensland, Brisbane, Queensland, Australia.
  • ARC Centre of Excellence, Plant Success in Nature and Agriculture, St. Lucia, Queensland, Australia.
  • School of Mathematical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia.
  • Department of Computer Science, University of Oxford, Oxford, United Kingdom.

ORCID-Profile: James G Lefevre, Brodie A J Lawson, Pamela M Burrage

Förderung

  • Australian Research Council Centre of Excellence for Plant Success in Nature and Agriculture

Zitieren

APA

Lefevre, J. G., Lawson, B. A. J., Burrage, P. M., Donovan, D. M., & Burrage, K. (2025). Optimal control of multiple myeloma assuming drug resistance and off-target effects. PLOS Computational Biology. https://doi.org/10.1371/journal.pcbi.1012225

Vancouver

Lefevre JG, Lawson BAJ, Burrage PM, Donovan DM, Burrage K. Optimal control of multiple myeloma assuming drug resistance and off-target effects. PLOS Computational Biology. 2025. doi:10.1371/journal.pcbi.1012225

BibTeX
@article{Lefevre2025,
  author = {Lefevre, James G and Lawson, Brodie A J and Burrage, Pamela M and Donovan, Diane M and Burrage, Kevin},
  title = {Optimal control of multiple myeloma assuming drug resistance and off-target effects},
  journal = {PLOS Computational Biology},
  year = {2025},
  doi = {10.1371/journal.pcbi.1012225}
}
Kostenlos starten →